Charles River Laboratories International (NYSE:CRL) Price Target Raised to $334.00

Charles River Laboratories International (NYSE:CRL) had its price target lifted by Robert W. Baird from $291.00 to $334.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price objective indicates a potential upside of 13.10% from the company’s previous close.

A number of other brokerages have also recently weighed in on CRL. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Argus set a $330.00 price objective on Charles River Laboratories International in a research note on Thursday, September 17th. Barclays reiterated an “overweight” rating and set a $330.00 target price on shares of Charles River Laboratories International in a report on Friday. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 11th. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $278.38.

Charles River Laboratories International Trading Up 6.5%

Shares of CRL stock opened at $295.30 on Friday. The firm has a market cap of $14.10 billion, a P/E ratio of -60.89, a PEG ratio of 2.80 and a beta of 1.40. Charles River Laboratories International has a 1-year low of $144.26 and a 1-year high of $303.30. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm’s 50-day simple moving average is $269.08 and its 200-day simple moving average is $212.48.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the business earned $3.12 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts forecast that Charles River Laboratories International will post 11.33 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. This represents a 15.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This trade represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 165,990 shares of company stock worth $42,606,388 in the last ninety days. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in the company. Continuum Advisory LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at about $30,000. SHP Wealth Management purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $85,000. Eurizon Capital SGR S.p.A. purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $104,000. Hilltop National Bank grew its stake in Charles River Laboratories International by 28.7% during the 2nd quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 127 shares in the last quarter. Finally, Trust Asset Management LLC purchased a new stake in Charles River Laboratories International during the 2nd quarter worth approximately $129,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: 2026 earnings outlook improved: Charles River issued EPS guidance of approximately $11.45, above the analyst consensus estimate of $11.33 and at the high end of its previously stated range. Revenue guidance of about $3.9 billion was maintained and is broadly in line with expectations. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Positive Sentiment: 2030 growth targets added a longer-term catalyst: Management outlined its 2030 growth projections, which investors viewed as evidence that Charles River can expand earnings and revenue beyond the current year. The company’s outlook helped drive the stock higher and places more emphasis on execution across its research and laboratory services businesses. Charles River Laboratories Stock Rises After Unveiling 2030 Growth Targets
• Neutral Sentiment: Investor focus shifts to execution: The Investor Day presentation and transcript provided additional detail on the company’s strategy and outlook, but the long-term targets remain dependent on sustained demand, operational improvement and successful execution. Revenue expectations for 2026 were not materially above consensus. Charles River Laboratories Analyst and Investor Day Transcript

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.